Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTK7-CAR gamma delta T cells
- Development stage
- Preclinical
- Lead developer
- Emory University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
PTK7-CAR gamma delta T cells are an experimental cellular immunotherapy being developed for the treatment of T-cell acute lymphoblastic leukemia (T-ALL). This therapeutic approach utilizes gamma delta (γδ) T cells, which possess innate antitumor activity and MHC-independent antigen recognition, as a platform for chimeric antigen receptor (CAR) engineering. By targeting Protein Tyrosine Kinase 7 (PTK7)—a transmembrane pseudokinase overexpressed in T-ALL but minimally expressed in normal γδ T cells—this therapy aims to overcome common CAR-T challenges such as fratricide and T-cell aplasia. To enhance therapeutic efficacy, the γδ T cells are expanded ex vivo in the presence of transforming growth factor beta (TGFβ), which has been shown to improve their persistence and bone marrow trafficking in murine models.
- Other names
- TGFβ-expanded PTK7 CAR γδ T cellsPTK7-directed CAR gamma delta T cellsPTK-7-directed CAR gamma delta T cellsPTK 7-directed CAR gamma delta T cells
02
Targets
Native gamma delta T-cell receptor ligandPTK7 (Protein tyrosine kinase 7)GD2MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on PTK7-CAR gamma delta T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTK7-CAR gamma delta T cells.